Medicinus - Dexa Medica

NF-kB, TNFα, VCAM-1 and P-selectin. These markers
were important in inflammation related to atherosclerosis.
RAW 264.7 cells were able to down-regulate
the expressions of NF-kB by 45% (Fig. 1a), TNFα by
22% (Fig. 1b), VCAM-1 by 22% (Fig. 1c) and P-selectin
(Fig. 1d) by 20%. To ascertain the effect of DLBS1033
on macrophage, a macrophage binding assay to Vascular
Smooth Muscle Cells (VSMC) was conducted. As
seen in Fig.2, the attachment of monocytic RAW264.7
to VSMC was reduced to a level 10% of the control
cells. This suggested that reduction in expression of
adhesion molecules V-CAM and P-Selectine, were
able to reduce binding macrophage to VSMC.
Effects of DLBS1033 on Plaque Stabilization Marker
Plaque stabilization is also related to prevention of
acute CVD events. Suppression of about 25-50% in
the expression of MMP-9, a marker of plaque instability
was seen after treatment with DLBS1033 (Fig.
3) suggesting that this bioactive protein fraction has
the ability to control plaque stabilization.
Effects of DLBS1033 on Smooth Muscle Cells Viability
and Migration
We observed the effects of DLBS1033 on VSMC cell
viability. As can be inferred in Fig. 4a, DLBS1033, was
able to inhibit the proliferation of the VSMC significantly.
In addition, after 4 hours following administration
of DLBS1033, VSMC migration in the presence
of Angiotensin II was significantly reduced to a level
2-fold lower when compared to that of Angiotensin
II alone (Fig. 4b). The data suggested that DLBS1033
had a positive effect on smooth muscle cells viability
and migration. Thus reducing the potentiality of
plaque enlargement via intimal medial thickness
and/or plaque stability. In addition, the expression of
original article
Control DLBS1033
Figure 2. Effect of DLBS1033 on the attachment of monocytic RAW246.7 cells to Vascular Smooth Muscle Cells (VSMC).
research
growth signal JAK1 (Fig. 5a) and STAT1 (Fig. 5b) were
also reduced in the presence of DLBS1033 signifying
the growth arresting effect of DLBS1033 on VSMC.
Figure 3. Effect of 0.5 μg/ml DLBS1033 on expression of MMP-9.
MEDICINUS 24(1), January 2011 21